Advertisement
CAI vs FMED
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a Hold and FMED is a Buy.
CAI in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
CAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 9 of 11 cases where CAI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CAI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 46 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAI as a result. In 22 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for CAI turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 10 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CAI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.049) is normal, around the industry mean (3.498). P/E Ratio (2.634) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (130.981) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Aroon Indicator for FMED shows an upward move is likely
FMED's Aroon Indicator triggered a bullish signal on November 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 143 similar instances where the Aroon Indicator showed a similar pattern. In 129 of the 143 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FMED as a result. In 51 of 58 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for FMED just turned positive on November 09, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in 28 of 33 cases over the following month. The odds of a continued upward trend are 85%.
FMED moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for FMED crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in 171 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 41 cases where FMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
FMED broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
CAI | ||
|---|---|---|
OUTLOOK RATING 1..100 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 46 | |
PRICE GROWTH RATING 1..100 | 44 | |
P/E GROWTH RATING 1..100 | 8 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CAI | FMED | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | N/A |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 84% |
| Advances ODDS (%) | 8 days ago 69% | 2 days ago 84% |
| Declines ODDS (%) | 6 days ago 80% | 10 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | N/A | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CAI’s FA Score shows that 1 FA rating(s) are green while .
- CAI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CAI’s TA Score shows that 4 TA indicator(s) are bullish.
- CAI’s TA Score: 4 bullish, 4 bearish.
Price Growth
CAI (@Biotechnology) experienced а -25.63% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CAI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CAI has been loosely correlated with TWST. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To CAI | 1D Price Change % | ||
|---|---|---|---|---|
| CAI | 100% | -4.46% | ||
| TWST - CAI | 45% Loosely correlated | -2.37% | ||
| RXRX - CAI | 42% Loosely correlated | -6.70% | ||
| BMEA - CAI | 38% Loosely correlated | -8.07% | ||
| ABCL - CAI | 38% Loosely correlated | -0.32% | ||
| ABSI - CAI | 36% Loosely correlated | -7.69% | ||
More | ||||
FMED and
Correlation & Price change
A.I.dvisor indicates that over the last year, FMED has been loosely correlated with TWST. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if FMED jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To FMED | 1D Price Change % | ||
|---|---|---|---|---|
| FMED | 100% | +0.56% | ||
| TWST - FMED | 64% Loosely correlated | -2.37% | ||
| RGEN - FMED | 62% Loosely correlated | -2.77% | ||
| TXG - FMED | 61% Loosely correlated | -3.31% | ||
| NTRA - FMED | 60% Loosely correlated | -2.62% | ||
| CAI - FMED | 57% Loosely correlated | -4.46% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SIXF | 35.08 | N/A | N/A |
| AllianzIM U.S. Equity 6 Month Buffer10 Feb/Aug ETF (SIXF) | |||
| EALT | 36.08 | -0.11 | -0.30% |
| Innovator U.S. Equity 5 to 15 Buffer ETF - Quarterly (EALT) | |||
| URTH | 203.86 | -0.96 | -0.47% |
| iShares MSCI World ETF (URTH) | |||
| SMDV | 75.39 | -0.36 | -0.48% |
| ProShares S&P SmallCap 600 Dividend Aristocrats ETF (SMDV) | |||
| MUND | 101.10 | -0.75 | -0.74% |
| Northern Trust 2055 Tax-Exempt Distributing Ladder ETF (MUND) | |||